Reuters logo
BRIEF-Epizyme expands clinical collaboration with Genentech
June 26, 2017 / 10:45 AM / 5 months ago

BRIEF-Epizyme expands clinical collaboration with Genentech

June 26 (Reuters) - Epizyme Inc

* Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc

* Epizyme inc - expanded its clinical collaboration with genentech, a member of roche group

* Epizyme inc - under new agreement, tazemetostat administered in combination with atezolizumab will be evaluated in a phase 1b/2 clinical study

* Epizyme inc - financial terms are not disclosed and epizyme will retain global development and commercialization rights to tazemetostat.

* Epizyme inc - genentech will sponsor planned phase 1b/2 clinical trial, which is expected to be initiated by end of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below